Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director Sells $1,451,880.00 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction on Friday, June 21st. The stock was sold at an average price of $39.24, for a total value of $1,451,880.00. Following the transaction, the director now directly owns 136,998 shares of the company’s stock, valued at approximately $5,375,801.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Apellis Pharmaceuticals Stock Up 0.1 %

APLS opened at $40.43 on Thursday. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.77 and a quick ratio of 3.02. The stock has a market capitalization of $4.91 billion, a price-to-earnings ratio of -11.68 and a beta of 0.95. The business has a 50-day moving average of $42.90 and a two-hundred day moving average of $55.06. Apellis Pharmaceuticals, Inc. has a 12 month low of $19.83 and a 12 month high of $92.61.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). The company had revenue of $172.33 million during the quarter, compared to analysts’ expectations of $163.37 million. Apellis Pharmaceuticals had a negative return on equity of 160.77% and a negative net margin of 79.67%. The firm’s revenue was up 284.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.56) EPS. On average, research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.1 earnings per share for the current year.

Institutional Trading of Apellis Pharmaceuticals

A number of institutional investors have recently modified their holdings of APLS. Assenagon Asset Management S.A. grew its holdings in shares of Apellis Pharmaceuticals by 109.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock worth $128,400,000 after purchasing an additional 1,121,497 shares during the period. Norges Bank purchased a new stake in shares of Apellis Pharmaceuticals during the 4th quarter worth about $56,640,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Apellis Pharmaceuticals by 38.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock worth $147,277,000 after purchasing an additional 677,098 shares during the period. Polar Capital Holdings Plc grew its holdings in shares of Apellis Pharmaceuticals by 126.6% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock worth $40,089,000 after purchasing an additional 588,875 shares during the period. Finally, Iron Triangle Partners LP purchased a new stake in shares of Apellis Pharmaceuticals during the 1st quarter worth about $32,329,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Analysts Set New Price Targets

APLS has been the subject of several research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday, May 8th. JPMorgan Chase & Co. lifted their price objective on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Mizuho dropped their price objective on Apellis Pharmaceuticals from $60.00 to $52.00 and set a “neutral” rating for the company in a research report on Monday, April 29th. Wedbush dropped their price objective on Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Finally, Wells Fargo & Company dropped their price objective on Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating for the company in a research report on Thursday, May 23rd. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $74.38.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).